Cited by 1,031Chemotherapy-induced cardiotoxicity and mitigationCardiac tumors and thrombiHIV-related health complications and treatments

The DOI matches its Crossref record; 221 of the 221 references it cites were found in a registry or an index.

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Open access

Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A.R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M.G., Orecchia, R., de Azambuja, E., Zamorano, J.L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C.M., Dent, S., Jordan, K.·2020·Annals of Oncology

DOI 10.1016/j.annonc.2019.10.023PMC PMC8019325

Open this paper in CoChat — free account Open PDF

Abstract

Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are interlinked through common risk factors, coincident in an ageing population, and are connected biologically through some deleterious effects of anticancer treatment on CV health. Anticancer therapies can cause a wide spectrum of short- and long-term cardiotoxic effects. An explosion of novel cancer therapies has revolutionised this field and dramatically altered cancer prognosis. Nevertheless, these new therapies have introduced unexpected CV complications beyond heart failure. Common CV toxicities related to cancer therapy are defined, along with suggested strategies for prevention, detection and treatment. This ESMO consensus article proposes to define CV toxicities related to cancer or its therapies and provide guidance regarding prevention, screening, monitoring and treatment of CV toxicity. The majority of anticancer therapies are associated with some CV toxicity, ranging from asymptomatic and transient to more clinically significant and long-lasting cardiac events. It is critical however, that concerns about potential CV damage resulting from anticancer therapies should be weighed against the potential benefits of cancer therapy, including benefits in overall survival. CV disease in patients with cancer is complex and treatment needs to be individualised. The scope of cardio-oncology is wide and includes prevention, detection, monitoring and treatment of CV toxicity related to cancer therapy, and also ensuring the safe development of future novel cancer treatments that minimise the impact on CV health. It is anticipated that the management strategies discussed herein will be suitable for the majority of patients. Nonetheless, the clinical judgment of physicians remains extremely important; hence, when using these best clinical practices to inform treatment options and decisions, practitioners should also consider the individual circumstances of their patients on a case-by-case basis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.annonc.2019.10.023

Cites

221 of 221 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2021) · PubMed · doi:10.1093/eurheartj/ehab670 · Cited by 20,604
Self-citation
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.592 · Cited by 5,866
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945

Show all 221 references

Sorted by citations

Items 801–900 of 999

Adjuvant Weekly Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer without Risk Factors of Cardiotoxicity. Possibility of Omitting Cardiac Monitoring during Treatment.Preprint
Mizuno, T., Tsunoda, A., Tono, Y., Oda, H., Ishihara, M., Saito, K., & Yamashita, Y. (2020) · doi:10.21203/rs.3.rs-50661/v1
CARMO - Implementation of a Prospective Cardiac Monitoring Program for the Early Detection of Cardiac Dysfunction in Oncological Phase I/II TrialsPreprint
Glutsch, V., Sayheli, C., Liu, D., Christa, M., Morbach, C., Schilling, B., Jahns, R., Bargou, R. C., & Goebeler, M.-E. (2021) · Research Square · doi:10.21203/rs.3.rs-210329/v1
Correlation of cardiovascular risk factors with the SCORE scale and the subjective global assessment test in patients with breast cancer
León, S. J. A., Martínez, C. S., & León, M. A. (2021) · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · doi:10.18004/rvspmi/2312-3893/2021.08.01.106
A Need for Even More Evidence-Based Comparative Studies in Cardio-Oncology?
Kwong, R. Y. K., & Chandrashekhar, Y. S. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2021.04.001
Cardiovascular Oncologic Emergencies
Nafee, T., Debs, D., Planek, M. I. C., Zimmerman, A., Charlton, T., Dimza, M., Murphy, A. C., Dobbin, S. J. H., Lang, N. N., Tyebally, S. M., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-67123-5_21
Self-citation
The interactions between antihypertensive drugs and novel anticancer therapy
Tadic, M. V., & Grassi, G. M. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002806
Kanker als hartenbreker: cardio-oncologie, meer dan alleen hartfalen?
von Kemp, B. A., Droogmans, S., & Cosyns, B. (2021) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.77.21.068
Early Tracking of Radiation-Induced Cardiotoxicity
Patel, B. D., Bianco, C. M., & Sengupta, P. P. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.04.007
2. Clinical Pharmacology in Patients with Cancer as a Comorbidity
Shimokata, T. (2021) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.52.70
Carcinoma de seno y cardiotoxicidad
Roncancio-Martínez, H., & Jaramillo, M. (2021) · Revista Colombiana de Cardiología · doi:10.24875/rccar.m21000048
Anthracycline/Trastuzumab Cardiac Toxicity
Yu, C., Pathan, F. K., & Negishi, K. (2021) · Springer eBooks · doi:10.1007/978-3-030-70998-3_2
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
Bueno, H., Moura, B., Lancellotti, P., & Bauersachs, J. K. (2021) · Cardiologia Croatica · doi:10.15836/ccar2021.140
Self-citation
Protocolo de tratamiento de la cardiotoxicidad en la cardio-oncología
Zatarain‐Nicolás, E., Flores, C. H., Bermejo, J., & Fernández‐Avilés, F. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.09.016
Cardio-oncología y cardiotoxicidad
Flores, C. H., Zatarain‐Nicolás, E., Bermejo, J., & Fernández‐Avilés, F. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.09.013
Prognostic Factors for Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients Treated with Current Anthracycline RegimensPreprint
Egashira, K., Sueta, D., Tomiguchi, M., Hidaka, K., Goto‐Yamaguchi, L., Sueta, A., Komorita, T., Takae, M., Oike, F., Fujisue, K., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1084573/v1
Miocardiopatía dilatada
Campos, A. G., Domínguez, M. P., & González-Juanatey, B. D. F. Y. J. R. (2021) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2021.09.021
THROUGH AND BEYOND COVID-19 PANDEMIC: A NEW SCENARIO FOR CARDIONCOLOGY
Tarantini, L., Camerini, A., Canale, M. L., Bisceglia, I., Gabrielli, D., Colvicchi, F., Gulizia, M. M., & Navazio, A. (2021) · Annals of Research in Oncology · doi:10.48286/aro.2021.27
Hypertension and renal failure prevention and management after cancer therapy
Lang, N. N., Dobbin, S. J. H., Herrmann, S. M., Herrmann, J., & Touyz, R. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00041-6
Self-citation
Prevention of heart failure and cardiomyopathy in patients with cancer
Alvarez-Cardona, J. A., & Lenihan, D. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00016-7
Self-citation
Cancer survivorship and comorbidity disease risk after cancer treatment
Clasen, S. C., Kondapalli, L., & Carver, J. R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00033-7
Self-citation
Impact of a COmprehensive Cardiac REhabilitation Framework Among High Cardiovascular Risk Cancer Survivors: Rationale and Study Design of the CORE TrialPreprint
Viamonte, S., Joaquim, A. V., Alves, A. J., Capela, A., Vilela, E., Ferreira, C., Rato, N. D., Duarte, B., Santos, M., Tavares, A. I., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4004924
Prevention and management of cardiomyopathy and heart failure in cancer survivors
Alvarez-Cardona, J. A., & Lenihan, D. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00036-2
Self-citation
Breast Cancer with Associated Problems
Chintamani, C., Tandon, M., & Ghosh, J. (2022) · Springer eBooks · doi:10.1007/978-981-16-4546-4_24
Possibilities of Early Diagnosis of Anthracycline-Induced Cardiomyopathy during Chemotherapy for Breast Cancer
Александрович, С. В., Курбат, М. Н., Александровна, К. И., Юрьевич, Р. А., Евстрат, Е. А., & Смирнова, Т. А. (2022) · Кардиология в Беларуси · doi:10.34883/pi.2022.14.1.009
Is echocardiography invincible for the diagnosis of cancer therapy-related cardiac dysfunction?: Another emerging imaging option
Sueta, D., & Tsujita, K. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.04.051
Effect of arterial hypertension on quality of life and anxiety in middle-aged patients with breast cancer
Григорьевна, П. Е., Вологдина, И. В., Жабина, Р. М., & Красильникова, Л. А. (2021) · HERALD of North-Western State Medical University named after I I Mechnikov · doi:10.17816/mechnikov88811
Cardiovascular Health
Dent, S. F., Kikuchi, R., Gilchrist, S. C., & Melloni, C. (2021) · Springer eBooks · doi:10.1007/978-3-030-75377-1_16
Self-citation
Onkologie und Versorgung in Fach- und Publikumsmedien
(2020) · Der Onkologe · doi:10.1007/s00761-020-00868-6
5-year study of the effect of cardiac monitoring on the overall survival of patients with chronic lymphocytic leukemia receiving targeted therapy with ibrutinib
Emelina, E. I., Gendlin, G. E., & Nikitin, I. G. (2022) · Kardiologiia · doi:10.18087/cardio.2022.4.n1882
Iatrogenic heart failure
Rosen, S. D., & Khwanda, A. (2022) · doi:10.1093/med/9780198766223.003.0010
Cardiotoxicity: Will we ever unravel it?
Magalhães, A. (2022) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2022.07.006
Diagnostic Methods of Cardiac Immunotherapy Damaging
Manno, G., Lisi, D. D., & Novo, G. (2022) · Current clinical pathology · doi:10.1007/978-3-030-97744-3_6
Krebstherapien und Herzerkrankungen – ein komplexes Wechselspiel
Birner, C. M. (2022) · Aktuelle Kardiologie · doi:10.1055/a-1788-2461
Prognostic Factors for Cancer Therapeutics-Related Cardiac Dysfunction in Breast Cancer Patients Treated with Current Anthracycline RegimensPreprint
Egashira, K., Sueta, D., Tomiguchi, M., Hidaka, K., Goto‐Yamaguchi, L., Sueta, A., Komorita, T., Takae, M., Oike, F., Fujisue, K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1084573/v2
The Role of Multimodality Cardiac Imaging in Patients Undergoing Cancer Treatment
Wengrofsky, P., & Feldman, S. A. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01825-y
Possibilities of a new method for evaluating myocardial work in patients with breast cancer after anthracycline chemotherapy
Saidova, M. A., Avalyan, A. A., & Ощепкова, Е. В. (2022) · Systemic Hypertension · doi:10.38109/2075-082x-2022-2-11-16
Combined immune-mediated adverse events in treatment with immune checkpoint inhibitors
Баллюзек, М. Ф., Анатольевна, П. С., Олегович, К. С., Машкова, М., & Хайманова, Д. Г. (2022) · Voprosy Onkologii · doi:10.37469/0507-3758-2022-68-6-846-853
CHRONIC HEART FAILURE AS A MANIFESTATION OF CARDIOTOXICITY IN CANCER PATIENTS
Федорец, В. Н., Жабина, Р. М., Майстренко, Д. Н., Вологдина, И. В., Красильникова, Л. А., Василенко, В. С., & Овчинников, И. В. (2023) · Медицина: теория и практика · doi:10.56871/mtp.2022.37.71.009
Impact of anticancer therapy on the dynamics of myocardial damage markers, indicators of endothelial dysfunction and oxidative stress in patients with lymphomas
Николаевна, А. О., Александровна, Б. Д., Ilgisonis, I. S., Belenkov, Y. N., Ершов, В. И., Gadaev, I. Y., Bochkarnikova, O. V., & Sokolova, I. Y. (2022) · Medical news of the North Caucasus · doi:10.14300/mnnc.2022.17091
Predicting heart failure symptoms in breast cancer patients receiving Trastuzumab using cardiovascular magnetic resonance strain assessmentPreprint
Yeo, J. L., Taha, A. H., Mahjob, M., & Sosin, M. D. (2023) · Research Square · doi:10.21203/rs.3.rs-2553813/v1
Failure of Guidelines and Consensus Statements to Recommend Follow-up for Chronic Cardiovascular Conditions
Patel, K., Maestas, C. M., Petrechko, O., Boja, H., & Blankenship, J. C. (2023) · Heart & Lung · doi:10.1016/j.hrtlng.2023.01.002
Chronic lymphoproliferative diseases and cardiovascular risk (a literature review)
Samura, B. B., & Panasenko, M. O. (2022) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2022.5.266062
Data from Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors
He, X., Ji, J., Dai, X., Qdaisat, A. Z., Esteva, F. J., Hortobágyi, G. N., & Yeung, S. J. (2023) · doi:10.1158/1078-0432.c.6530691.v1
Metaheuristic Model of Gene Selection for Deep Learning Early Prediction of Cancer Disease Using Gene Expression DataPreprint
Joshi, A. A., & Aziz, R. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2896430/v1
Cardio-Protection Against Cancer Treatment-Related Cardiac Dysfunction: Who is at Risk?
Macedo, A. V. S., & Martins, W. D. A. (2022) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20230006
Cardiac monitoring of neoadjuvant chemotherapy in a patient with breast cancer
Рустамджонович, А. Ф., Уметовна, А. Э., Мацкеплишвили, С. Т., Артамонова, Е. В., Ахмедярова, Н. К., & Rakhmanzhanov, A. A. (2023) · Russian Journal of Cardiology and Cardiovascular Surgery · doi:10.17116/kardio202316031309
Moderne Therapie des Mammakarzinoms und gynäkologischer Tumoren: Nebenwirkungen erkennen und beherrschen
Engler, T., Walter, C. B., Volmer, L. L., Dannehl, D., Hartkopf, A. D., Nikolaou, K., & Brucker, S. Y. (2023) · Deutsches Ärzteblatt · doi:10.3238/persgyn.2023.06.23.01
CARDIOLOGIA EM FOCO: PREVENÇÃO, DIAGNÓSTICO E TRATAMENTOS ATUAIS
Almeida, A. B., & Horevicht, C. M. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809
A IMPORTÂNCIA DA CARDIO-ONCOLOGIA NA PREVENÇÃO DE EVENTOS CARDIOVASCULARES NO TRATAMENTO DO CÂNCER
de Siqueira, E. F., Guimarães, F. V., Dorvalino, J. D. S., Scalfi, L. C. M., & Taglietti, Z. R. (2023) · EPITAYA eBooks · doi:10.47879/ed.ep.2023809p312
Factors influencing physicians’ decision to conduct cardiovascular risk assessments among cancer patients: A Systematic ReviewPreprint
Teh, H. S., Subramaniam, S., Thiagarajan, M., & Hwong, W. Y. (2023) · Research Square · doi:10.21203/rs.3.rs-2979487/v1
Prevalence and Effects of Late Cardiotoxicity induced by Anthracyclines and/or Anti- HER2 Antibodies in Patients with Breast Cancer: a real world studyPreprint
Oliveira, C. C., Flores, R. F., Azevedo, R., Fontes, R., & Pereira, V. (2023) · Research Square · doi:10.21203/rs.3.rs-3138966/v1
Oral Oncolytics and Cardiovascular Risk Management and Monitoring
White, R. T., Sirek, M. E., & Marrs, J. C. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001458
Guidelines in Cardio-Oncology: The Balance Between Evidence and Expert Opinion
Leedy, D. J., Alhama-Belotto, M., Gwin, W. R., Kapoor, R., Minami, E., Chow, E. J., & Cheng, R. K.-H. (2023) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-023-01014-2
New Approaches to Cardiovascular Toxicity Assessment in Patients with Hematological Malignancies: A Literature Review
Евгеньевна, Д. О., Gimatdinova, G. R., Davydkin, I. L., Терешина, О. В., Sabanova, V. D., & Давыдкин, Г. И. (2023) · Clinical oncohematology · doi:10.21320/2500-2139-2023-16-3-331-336
Stress Echocardiography in Cancer Survivors After Chemo- and Radiotherapy
Simova, I. I., Samardjieva, M., & Picano, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-31062-1_35
Pediatric Stress Echocardiography
Henein, M., & Picano, E. (2023) · Springer eBooks · doi:10.1007/978-3-031-31062-1_37
A New Era of HER2 Directed Therapy –A Review of Cardiac Toxicities in Novel AntiHER2 Agents
Le-Kumar, T. (2023) · Medical Research Archives · doi:10.18103/mra.v11i10.4578
Chemotherapy-derived cardiotoxicity: a mini-review of the guidelines
D’Amato, M., Esposito, J. E., Dorizzi, R. M., Moretti, M., Vero, A., Toniato, E., Iorio, G. D., & POLILLI, E. (2023) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.23.00215-3
Hipertensão Arterial Sistêmica: identificação, manejo e implicações clínicas, durante a internação hospitalar do paciente oncológico
de Souza, D. C., Badin, R. C., & Manaças, L. R. A. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e14997.2023
Reliable left ventricular ejection fraction assessment: A fundamental need in cardio-oncology
Alvarez, J. A., & Divakaran, S. (2024) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2023.101781
Targeted Therapies and Immunotherapy
Kechagioglou, P., & Fuller-Shavel, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-51216-2_9
Cardiovascular Diseases in Oncological Patients Treated at a Tertiary Hospital in the Northern Macroregion of Rio Grande do Sul
Lorencini, G. A., & Rabello, R. D. S. (2023) · ABC Heart Failure & Cardiomyopathy · doi:10.36660/abchf.20230081
ATRIAL FIBRILLATION IN PATIENTS WITH CANCER (ANALYSIS OF LITERARY SOURCES)
Федорец, В. Н., Вологдина, И. В., Василенко, В. С., Григорьевна, П. Е., & Красильникова, Л. А. (2023) · Медицина: теория и практика · doi:10.56871/mtp.2023.43.39.002
Cardiovascular events associated with CDK4/6 inhibitors based on randomized controlled trials or cohort trials: a safety meta-analysisPreprint
Zhang, C.-R., Shen, G., Li, S., Ma, F., Li, H., Tang, Y., Li, Y., Li, Z., Zhu, Z., Qiu, T., et al. (2024) · medRxiv · doi:10.1101/2024.03.29.24305099
Physical exercise in the prevention of chemotherapy-induced cardiotoxicity: a systematic review with meta- analysisPreprint
Pedroni, A. S., Perius, C. A., Penna, G. B., & Macagnan, F. E. (2024) · Research Square · doi:10.21203/rs.3.rs-4214491/v1
THE POTENTIAL OF USING THE DYNAMICS OF ELECTROCARDIOGRAPHIC PARAMETERS IN DETECTING CARDIOTOXICITY 12 MONTHS AFTER THE END OF CHEMOTHERAPY FOR BREAST CANCER WITH DOXORUBICIN
Karputs, I. A., Snezhitskiy, V. А., Kurbat, M. N., Snezhitskaya, E. A., Kropa, О. М., Korabach, I. N., & Babenka, A. S. (2024) · Journal of the Grodno State Medical University · doi:10.25298/2221-8785-2024-22-2-127-136
Discovery of Plasma Proteins and Metabolites for Left Ventricular Cardiac Dysfunction in Pan-Cancer PatientsPreprint
Lal, J. C., Fang, M. Z., Hussein, M., Abraham, A., Hou, Y., Chung, M. K., Collier, P. H., & Cheng, F. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4820265
HIPERTENSÃO ARTERIAL SISTÊMICA E SUAS COMPLICAÇÕES CLÍNICAS
Nascimento, T. R., Maria, L. P., Firmino, M. D. S., de Sena, B. C. B., Lima, M., Batista, M. N., Gioia, I. B., Alves, P. I. S., da Silva, S. M., Silva, M. A. D. M. E., et al. (2024) · Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida · doi:10.36692/v16n1-54
Significance of Assessing Changes in Metalloproteinases (MMP-2 and MMP-3) Levels as a Potential Criterion for Early Cardiotoxicity Manifestations in Patients with Breast Malignancies after the Completion of Anthracycline-Based Chemotherapy
Александровна, К. И., Александрович, С. В., Курбат, М. Н., Горустович, О. А., Karpovich, Y. L., Шулика, В. Р., Юрьевич, Р. А., Смирнова, Т. А., & Бабенко, А. С. (2024) · Лабораторная диагностика Восточная Европа · doi:10.34883/pi.2024.13.1.008
FATORES DE RISCO COMUNS E TRATAMENTOS EMERGENTES PARA CASOS DE DOENÇAS CARDIOVASCULARES E CÂNCER
Bernardes, A. G. D. C., Wollmann, C. A. R., Horevicht, C. M., Ferreira, I. A. B. D. S., Figueredo, J. C., Ferreira, M. D., Sá, M. C., Senra, P. D. M., & Crepaldi, P. I. S. (2024) · EPITAYA eBooks · doi:10.47879/ed.ep.2024479p521
Cardioprotective effects of platycodon grandiflorum granules in HER2-positive early breast cancer patients receiving trastuzumab plus pertuzumab: study protocol for a double blind randomized controlled trial
Hao, W., Sun, C., Wu, C., Shi, Y., Qin, Y., & Liu, S. (2026) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-026-05402-6
Cardiotoxicity
Gonzalez, N. S., García‐Álvarez, A., Braña, I., Tabernero, J. M., & Oristrell, G. (2023) · Springer eBooks · doi:10.1007/978-3-030-93702-7_14-1
Cardio-Oncology: Risk Assessment and Management
Reilly, C. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-53705-9_17
Anti-cancer Therapies in Adults and Their Effects on Cardiovascular System: A Review
Habbal, R., Ouarrak, S., & Dehbi, H. (2024) · Cardiology and Angiology An International Journal · doi:10.9734/ca/2024/v13i3426
THE ROLE OF SOLAR AND ALTERNATIVE ENERGY IN DIRECTING OF THE BIOECOLOGICAL CHARACTERISTICS, CONSERVATION AND USE OF ESSENTIAL OIL PLANTS
Islamova, A. J. S. I. S. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-157
CARDIO-ONCOLOGY: A COMPREHENSIVE OVERVIEW AND INNOVATİVE APPROACHES
Mehraliev, S. S. O. M. O. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-114
QUANTITATIVE ANALYSIS OF PET IMAGING VIA THE FOUR-COMPARTMENT MODEL FOR LUNG CANCER ASSESSMENT
Gardashov, J. A. T. G. T. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-103
VENTURE INVESTMENT IN INDUSTRY: WORLD TENDENCIES AND EXPERIENCE OF AZERBAIJAN
Salayev, U. G. K. S. K. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-134
FİNİTE ELEMENT ANALYSİS OF THE OUTER TUBE PART OF THE ENDOSCOPE
Gambarov, R. G. R. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-63
PRODUCTION OF T7 RNA POLYMERASE ENZYME WITH RECOMBINANT DNA TECHNOLOGY
Altun, G. Y. C. A. C. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-84
COMPARISON OF STRUCTURES OF PIEZOELECTRIC CRYSTALS USED IN DOPPLER ULTRASONIC DIAGNOSTICS
Sultanov, K. R. O. S. O. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-42
MODERN INTELLECTUAL TECHNOLOGIES IN COMPUTER TOMOGRAPHY
Jabiyeva, E. A. A. J. A. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-05
HARNESSING MEDICAL INNOVATION: THE IMPACT OF ROBOTIC SIMULATORS AND VIRTUAL REALITY (VR) IN IMPROVING THE QUALITY OF MEDICAL EDUCATION
Jabiyeva, L. S. A. J. A. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-16
IMPROVING X-RAY IMAGE QUALITY BY ADAPTING THE RESPONSE FUNCTION OF AN ADAPTIVE OPTICS SYSTEM
Seyfullayev, E. R. F. S. F. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-53
NON-DESTRUCTİVE TESTİNG (NDT) APPLİCATİONS İN ENSURİNG THE RELİABİLİTY AND SAFETY OF MEDİCAL EQUİPMENT: A COMPREHENSİVE REVİEW
Aliyev, K. A. K. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-35
INVESTIGATION OF ANTI-CANCER PROPERTIES OF COMPONENTS EXTRACTED FROM POLAR MICROALGAE
Aydin, S. K. Z. A. Z., & Yeshiltash, G. Y. G. (2024) · PIRETC-Proceeding of The International Research Education & Training Centre · doi:10.36962/piretc30012024-74
Use of indicators of systolic and diastolic functions of the left ventricle in the diagnosis of early cardiotoxicity during chemotherapy with doxorubicin: An open, prospective, nonrandomized study
Karputs, I. A., Snezhitskiy, V. А., Kurbat, M. N., Harustovich, V. A., Karpovich, Y. I., Юрьевич, Р. А., Смирнова, Т. А., & Babenka, A. S. (2024) · Cardiosomatics · doi:10.17816/cs626047
How We Monitor Cardiac Health in Breast Cancer Survivors
Clasen, S. C., & Miller, M. E. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00757
1) Cancer Therapy-related Cardiac Dysfunction
Minami, H. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.1566
Genetic Susceptibility and Treatment Personalization in Acute Lymphoblastic Leukemia: A Comprehensive Review of Genetic Susceptibility and Targeted Therapies
Nirmalkar, N., Arora, I., Mishra, V. H., Bandre, G. R., & Tiwade, Y. R. (2024) · Journal of Applied Hematology · doi:10.4103/joah.joah_40_24
Cardio-oncology challenges and perspectives
Olteanu, G., Busnatu, Ș., Scafa‐Udriște, A., Licu, M., Neacşu, M. S., & Mititelu, M. (2024) · Farmacist ro · doi:10.26416/farm.218.3.2024.10038
Cardiotoxicity in Pediatric AML
Leger, K. J., & Narayan, H. K. (2024) · Pediatric oncology · doi:10.1007/978-3-031-63366-9_18
Androgenrezeptor-Signalweg-Inhibitoren und kardiovakuläre Ereignisse beim metastasierten Prostatakarzinom: Eine systematische Übersichtsarbeit und Metaanalyse
Uhlig, A. (2024) · Die Urologie · doi:10.1007/s00120-024-02464-7
Utilizing Echocardiography for Cardiotoxicity Detection in Breast and Colorectal Cancer Patients Undergoing ChemotherapyPreprint
Rezwani, A., Shekarchizadeh, M., Najafian, J., Massoudi, S., Zavar, R., Sadeghi, M., Darakhshandeh, A., Vafaei, Z., Akhavan, A., Khosravifarsani, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-5002446/v1
A longitudinal study of right ventricular function of patients with multiple myeloma treated with carfilzomib
Basin, S., Cezar, M., Fraix, A., Pace, N., Filippetti, L., Schulmann, S., Selton‐Suty, C., Huttin, O., Chabot, F., Chaouat, A., et al. (2024) · ERJ Open Research · doi:10.1183/23120541.00861-2024
Breaking Barriers in Cardiovascular and Cancer Care With Multimodal AI
Sun, C. L. F. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101433
CHEMOTHERAPY-INDUCED CARDIAC TOXICITY AND HEART FAILURE
Bayramzade, S. R., Mehdiyeva, N. I., & Bakhshiyev, M. (2025) · World of Medicine and Biology · doi:10.26724/2079-8334-2024-4-90-229-235
Krankheitsassoziierte, patientenbezogene und therapiebedingte Komplikationen beim multiplen Myelom
Rapi, A., Hampel, M., Mai, E. K., & Goldschmidt, H. (2025) · Die Onkologie · doi:10.1007/s00761-024-01659-z
Radiation and Chemotherapy-Induced Cardiac Toxicity in Breast Cancer
Madan, R., Dey, T., & Goyal, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-7755-6_44
Immune checkpoint inhibitors-associated cardiovascular toxicity in cancer therapy
Guerrero, P., Kapoor, K., & Bhatheja, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24742-2.00012-5

Authors: Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A. R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M. G., Orecchia, R., de Azambuja, E., Zamorano, J. L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C. M., Dent, S., & Jordan, K.
Affiliations: University of Milan (IT)
Washington University Medical Center (US)
University of South Florida (US)
Lahey Hospital and Medical Center (US)
Georgetown University (US)
University of Minnesota (US)
Mayo Clinic (US)
University of Kansas Medical Center (US)
Royal Brompton Hospital (GB)
Centre Hospitalier Universitaire de Liège (BE)
University of Chicago (US)
Vanderbilt University (US)
Stanford Medicine (US)
European Institute of Oncology (IT)
Hospital Universitario Ramón y Cajal (ES)
Washington University in St. Louis (US)
Tel Aviv University (IL)
Hospital of the University of Pennsylvania (US)
City Of Hope National Medical Center (US)
University of Pennsylvania (US)
Duke University (US)
Heidelberg University (DE)
ORCID: Curigliano, G.
Lenihan, D.
Fradley, M.
Ganatra, S.
Barac, A.
Blaes, A.
Porter, C.
Lyon, A.R.
Patel, A.
DeCara, J.
Mitchell, J.
Moslehi, J.
Witteles, R.
Orecchia, R.
Krone, R.
Iakobishvili, Z.
Carver, J.
Armenian, S.
Ky, B.
Cardinale, D.
Cipolla, C.M.
Dent, S.
Jordan, K.
Venue: Annals of Oncology
Publisher: Elsevier BV
Published: 2020-02
Volume: 31
Issue: 2
Pages: 171-190
ISSN: 0923-7534 (ISSN-L)
DOI: 10.1016/j.annonc.2019.10.023
PMC: PMC8019325
OpenAlex: W2999536665
Cited by: 1,031
References: 221
Citations by year: 2026: 108 · 2025: 152 · 2024: 168 · 2023: 189 · 2022: 188 · 2021: 143 · 2020: 83
FWCI: 93.28
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 366 d)
Locations: Annals of Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
ORBi (University of Liège) (submittedVersion, other-oa)
Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: HF
Genentech
Amgen
Servier
Pfizer
Bristol-Myers Squibb
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords: cardio-oncology, cardiotoxicity, cancer therapy, heart failure, cardiovascular screening, cardiovascular monitoring, novel cancer therapies, cardiovascular disease in cancer patients
MeSH terms: Antineoplastic Agents, Heart Diseases, Humans, Medical Oncology, Neoplasms, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks